Bone Biologics (BBLG) Projected to Post Quarterly Earnings on Monday

Bone Biologics (NASDAQ:BBLG) is anticipated to post its results after the market closes on Monday, May 11th. Analysts expect Bone Biologics to post earnings of ($0.54) per share for the quarter.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.34). On average, analysts expect Bone Biologics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Bone Biologics Stock Performance

Shares of NASDAQ:BBLG traded up $0.04 during midday trading on Monday, reaching $1.35. 880 shares of the company’s stock traded hands, compared to its average volume of 21,372. The stock has a 50 day moving average of $1.24 and a 200 day moving average of $1.56. The company has a market cap of $2.43 million, a price-to-earnings ratio of -0.36 and a beta of 0.89. Bone Biologics has a one year low of $1.05 and a one year high of $6.75.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC raised its position in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. Institutional investors own 34.30% of the company’s stock.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.